FDA orphan drug defeat has important implications for exclusivity

Agency acted in a way that was “arbitrary, capricious and not in accordance with the law” over treatment for rare disease developed by Catalyst Pharmaceuticals, says 11th Circuit appellate court

Get unlimited access to all IAM content